6SQB Sequans Communications S.A. ADS

OneCare, Inc. and Sequans Connect the Carewatch Remote Monitoring, Health/Medical Wearable to the IoT

Sequans Communications S.A. (NYSE: SQNS) and OneCare, Inc., are partnering to bring innovative health wearables to market using Sequans’ Monarch LTE-M/NB-IoT chip platform. The first device is the OneLife Carewatch, a revolutionary remote monitoring care platform recently launched on a leading US mobile network, and the two companies are developing additional wearable devices based on Sequans’ Monarch technology. The OneLife Carewatch is the only certified, mass-produced standalone wrist wearable on the market today that uses advanced LTE-M technology to securely transmit data and information to the cloud.

The OneLife Carewatch features a robust platform and delivers five days of battery life, thanks to the ultra low power consumption capability of Sequans’ Monarch. The OneLife Carewatch is an advanced and powerful solution for remote patient monitoring, delivering data, predictive analytics, and comprehensive health information over the cloud via the highly secure OneLife Guardian Carewatch APP. Another unique feature of the OneLife Care platform is its ability to integrate with all other health/medical devices and provide doctors, clinicians, and patients with a wide-ranging view of overall patient health, becoming a “hub of care.”

“We are dedicated to becoming the world’s leading remote care monitoring and population health monitoring platform,” said Thomas Glaser, Chairman, OneCare. “With our innovative Carewatch now connected by the always on and everywhere available LTE-M provided by Sequans’ ultra-efficient Monarch, patients are connected to their caregivers, and loved ones are connected to those needing monitoring for safety and protection in real time. Our partnership with Sequans and use of Monarch technology ensures we are well-positioned to positively impact lives. Our mission is to promote caring for each other—OneCare, OneLife, One Million Cared For.”

According to Juniper Research, the healthcare wearables market will reach $60 billion by 2023 and remote patient monitoring devices will become “must haves.” The research firm reports that the healthcare wearables market is being driven by improvements in remote patient monitoring technology and its increased adoption by medical institutions. The firm forecasts that 5 million people will be remotely monitored by healthcare providers by 2023.

“It is very exciting to provide our technology for the OneLife Carewatch wearable that will surely help millions of people,” said Georges Karam, Sequans CEO. “The Carewatch’s ability to provide accurate, real time health data that improves health outcomes and may save lives, makes it one of the most important IoT applications in use today. The OneLife Carewatch platform represents the future of healthcare and I believe it will drive the faster adoption of IoT.”

The OneLife Carewatch is powered by Sequans LTE-M/NB-IoT Platform. Monarch provides full support for power saving mode (PSM) and extended discontinuous reception (eDRX) to enable long battery life, and it provides enhanced coverage modes, including a +23 dBm power amplifier, that extend coverage for deep-indoor and remote deployments. For LTE positioning, Monarch incorporates the positioning technology of Polte for accurate, low power, indoor and outdoor positioning capability using only the LTE radio. Monarch delivers programmable RF filtering for global band support in a Single-SKU™, and proprietary dynamic power management technology, enabling rock bottom power consumption of 1 micro amp. Monarch is certified by operators around the world. .

About OneCare, Inc.

OneCare Inc. develops and commercializes carewear and solution platforms into best-in-class, stand-alone, cellular-connected wearables. Its OneLife Care platform is a leader in remote care mobile monitoring, providing software and data collection and management with a suite of proprietary, patented technologies designed to provide remote monitoring to millions of caregivers and patients.

About Sequans Communications

Sequans Communications S.A. (NYSE: SQNS) is a leading provider of single-mode 4G LTE semiconductor solutions for the Internet of Things (IoT) and a wide range of broadband data devices. Founded in 2003, Sequans has developed and delivered seven generations of 4G technology and its chips are certified and shipping in 4G networks around the world. Today, Sequans offers two LTE product lines: StreamrichLTE™, optimized for broadband devices, including CPE, mobile and portable routers, and high-performance IoT devices; and StreamliteLTE™, optimized for lower data rate and narrowband IoT devices, including wearables, trackers, and sensors. Sequans is based in Paris, France with additional offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Sweden, Taiwan, South Korea, and China. Visit Sequans online at .

EN
23/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sequans Communications S.A. ADS

Sequans Communications SA: 2 directors

Three Directors at Sequans Communications SA bought 435,000 shares at between 0.950USD and 1.088USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...

 PRESS RELEASE

Sequans and AmericanPharma Technologies Team Up to Protect Covid-19 Va...

PARIS & BOISE, Idaho--(BUSINESS WIRE)-- Sequans Communications S.A. (NYSE: SQNS) has joined forces with AmericanPharma Technologies and is providing the cellular IoT connectivity solution for AmericanPharma Tech’s PharmaWatch™ vaccine monitoring system that is currently protecting Covid-19 vaccine shipments and storage around the country. PharmaWatch is connected by Sequans’ Monarch technology, enabling it to upload its vaccine temperature monitoring data to the portal every 5 minutes via a secure and reliable cellular LTE-M network transmission. “PharmaWatch provides one of the most importan...

 PRESS RELEASE

Sequans to Participate in Needham 2021 Virtual Technology and Media Co...

PARIS--(BUSINESS WIRE)-- Sequans Communications S.A. (NYSE: SQNS), leading developer and provider of 5G and 4G solutions for broadband, critical, and massive IoT, announced today Georges Karam, CEO and Deborah Choate, CFO, will participate in the Needham Technology and Media Conference being held virtually May 17-20, 2021. Sequans will conduct one-on-one meetings on Monday, May 17th and Tuesday, May 18th between 8:00 am and 1:30 pm ET. The Company will participate in a fireside chat from 8:00 am to 8:40 am ET on Monday, May 17th. For more information about the Needham conference, or to sched...

 PRESS RELEASE

Sequans Communications Announces First Quarter 2021 Financial Results

PARIS--(BUSINESS WIRE)-- Sequans Communications S.A. (NYSE: SQNS), a leading developer and provider of 5G/4G chips and modules, today announced financial results for the first quarter ended March 31, 2021. First Quarter 2021 Summary Results Table: (in US$ millions, except share and per share data) Q1 2021   Q4 2020   Q1 2020 Revenue $12.3     $15.8     $8.8   Gross profit 6.2     7.1     4.5   Gross margin (%) 50.1 %   45.1 %   51.3 % Operating loss (5.8 )   (5.4 )   (7.8 ) Net loss ...

 PRESS RELEASE

Sequans Announces $50 Million Financing to Strengthen Balance Sheet

PARIS--(BUSINESS WIRE)-- Sequans Communications S.A. (NYSE: SQNS), leading developer and provider of 5G and 4G solutions for broadband, critical, and massive IoT, announced today the signing of a $50 million private financing with Lynrock Lake Master Fund LP, a fund managed by Lynrock Lake LP (“Lynrock Lake”), an investment management firm with approximately $1.2 billion of assets under management. The financing consists of $10 million of American Depository Shares (ADS) and $40 million principal amount of convertible debt. The financing is scheduled to close April 9, 2021. “A stronger balanc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch